Maxvax Biotechnology

麦克斯瓦克斯生物技术

LLC

有限责任公司

(USA

美国

)

)

recently announced that it has

最近宣布它已经

received funds from

收到资金来自

the Gates Foundation to

盖茨基金会

support

支持

the development of

的发展

its

它的

recombinant respiratory syncytial virus (RSV) maternal vaccine

重组呼吸道合胞病毒（RSV）母体疫苗

candidate

候选人

.

。

The funding will support

资金将用于支持

a

a

Phase

阶段

1

1

clinical trial

临床试验

, an important first step on the road to understanding how the vaccine candidate performs in

，这是了解候选疫苗表现的重要第一步

people

人们

.

。

Currently the

当前的

r

r

e is only one

只有一个

maternal

母亲的

RSV vaccine

呼吸道合胞病毒疫苗

licensed for use globally. T

全球使用许可。T

he

他

new

新

Maxvax

最大疫苗接种量

candidate

候选人

evaluates

评估

a

a

fully liquid

完全液态

formulation to simplify vaccine

简化疫苗的配方

delivery and

交付和

utilizes a manufacturing process designed to

利用专为...设计的制造工艺

be affordable

负担得起

for low- and middle-income countries.

适用于低收入和中等收入国家。

Maxvax’s

马克斯瓦克斯的

efforts to deliver innovative and affordable vaccine products worldwide

全球范围内提供创新且价格合理的疫苗产品的努力

and

和

contribut

贡献

e

e

to the advancement of global public health

促进全球公共卫生的发展

will be further strengthened with this funding

将会通过这笔资金进一步加强

.

。

RSV

呼吸道合胞病毒

is one of the leading causes of severe lower respiratory tract infections in infants and young children.

是导致婴儿和幼儿严重下呼吸道感染的主要原因之一。

World Health Organization

世界卫生组织

data show that RSV causes approximately 33 million infections annually among children under five

数据显示，RSV每年导致约3300万五岁以下儿童感染。

years of age

岁年龄

, resulting in 3.6 million hospitalizations and 10

，导致360万人住院和10人

0

0

,000 deaths

，000人死亡

. A

。A

bout half of

大约一半

these deaths

这些死亡事件

occur in infants under six months of age.

发生在六个月以下的婴儿身上。

Importantly,

重要的是，

9

9

7

7

% of pediatric RSV mortality occurs in low- and middle-income

%的儿科RSV死亡发生在低收入和中等收入国家。

countries

国家

.

。

Maxvax is developing a recombinant RSV maternal vaccine designed for maternal immunization. By vaccinating pregnant women, maternal antibodies can be transferred through the placenta to the infant, providing protection during the critical early months after birth

Maxvax 正在开发一种重组 RSV 母体疫苗，专为孕妇接种设计。通过为孕妇接种疫苗，母体抗体可以通过胎盘传递给婴儿，为其出生后关键的早期月份提供保护。

when infants are at highest risk

婴儿面临最高风险时

.

。

T

T

he company will conduct a Phase

公司将进行一期

1

1

clinical trial in

临床试验在

non-pregnant

非怀孕的

healthy

健康

adults

成年人

to evaluate the vaccine’s safety and

评估疫苗的安全性和

ability to elicit an immune response

诱发免疫反应的能力

. This program will expand Maxvax’s maternal vaccine pipeline

。该计划将扩大Maxvax的母体疫苗管道

to potentially

潜在地

offer an accessible, affordable solution to reduce the risk and severity of RSV infection in newborns—particularly benefiting low- and middle-income countries and supporting global maternal and child health.

提供一种可及且负担得起的解决方案，以降低新生儿RSV感染的风险和严重程度——尤其使低收入和中等收入国家受益，并支持全球母婴健康。

About Maxvax

关于Maxvax

Maxvax is a global biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative vaccines and novel adjuvants. Guided by the values of

麦克斯瓦克斯是一家全球生物制药公司，致力于创新疫苗和新型佐剂的研究、开发、生产和商业化。在以下价值观的指导下

Integrity, Innovation, Collaboration, and Global Service

诚信、创新、协作、全球服务

, Maxvax is committed to addressing major public health challenges and delivering effective solutions for the prevention and control of infectious diseases.

，迈科维致力于应对重大的公共卫生挑战，提供预防和控制传染病的有效解决方案。

The company focuses on both human and veterinary (including companion animal) vaccines and has built strong technology platforms in novel adjuvants, recombinant proteins, and immune evaluation. Leveraging these strengths, Maxvax has established a robust pipeline of

该公司专注于人类和兽医（包括伴侣动物）疫苗，并在新型佐剂、重组蛋白和免疫评估方面建立了强大的技术平台。利用这些优势，Maxvax 已建立了一个强大的产品管线。

breakthrough vaccines targeting infectious, allergic, and oncological diseases—three of which have already entered clinical development.

针对传染性、过敏性和肿瘤性疾病——其中三种已经进入临床开发阶段的突破性疫苗。